DK0858328T3 - Stabile præparater indeholdende N-propargyl-1-aminoindan - Google Patents

Stabile præparater indeholdende N-propargyl-1-aminoindan

Info

Publication number
DK0858328T3
DK0858328T3 DK96930344T DK96930344T DK0858328T3 DK 0858328 T3 DK0858328 T3 DK 0858328T3 DK 96930344 T DK96930344 T DK 96930344T DK 96930344 T DK96930344 T DK 96930344T DK 0858328 T3 DK0858328 T3 DK 0858328T3
Authority
DK
Denmark
Prior art keywords
pct
aminoindan
propargyl
preparations containing
sec
Prior art date
Application number
DK96930344T
Other languages
English (en)
Inventor
Peskin Tirtsah Berger
Fanny Caciularu
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11068003&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0858328(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of DK0858328T3 publication Critical patent/DK0858328T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid Fuels And Fuel-Associated Substances (AREA)
DK96930344T 1995-09-20 1996-09-18 Stabile præparater indeholdende N-propargyl-1-aminoindan DK0858328T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11535795A IL115357A (en) 1995-09-20 1995-09-20 Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
PCT/IL1996/000115 WO1997012583A2 (en) 1995-09-20 1996-09-18 Stable compositions containing n-propargyl-1-aminoindan

Publications (1)

Publication Number Publication Date
DK0858328T3 true DK0858328T3 (da) 2007-09-03

Family

ID=11068003

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96930344T DK0858328T3 (da) 1995-09-20 1996-09-18 Stabile præparater indeholdende N-propargyl-1-aminoindan

Country Status (13)

Country Link
US (1) US6126968A (da)
EP (1) EP0858328B1 (da)
JP (1) JP4108750B2 (da)
AT (1) ATE362755T1 (da)
AU (1) AU728524B2 (da)
CA (1) CA2232310C (da)
DE (1) DE69637096T2 (da)
DK (1) DK0858328T3 (da)
ES (1) ES2287940T3 (da)
HU (1) HU225859B1 (da)
IL (1) IL115357A (da)
PT (1) PT858328E (da)
WO (1) WO1997012583A2 (da)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
WO2001030339A1 (en) 1999-10-27 2001-05-03 Teva Pharmaceutical Industries, Ltd. Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder
WO2004045515A2 (en) 2002-11-15 2004-06-03 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
AU2005269416B2 (en) * 2004-07-26 2011-07-28 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
WO2006052254A2 (en) * 2004-11-10 2006-05-18 Teva Pharmaceutical Industries Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
US8367105B2 (en) 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
ATE521343T1 (de) * 2004-11-24 2011-09-15 Teva Pharma Im mund zerfallende zusammensetzungen von rasagilin
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
CA2596664A1 (en) * 2005-02-17 2006-08-24 Teva Pharmaceutical Industries Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
BRPI0608209A2 (pt) 2005-02-23 2010-11-09 Teva Pharma mistura de partìculas, composição sólida, método para tratamento de um paciente com mal de parkinson, processo para preparação de uma composição, e, composição farmacêutica sólida
JP2009521402A (ja) 2005-11-17 2009-06-04 テバ ファーマシューティカル インダストリーズ リミティド プロパルギル化アミノインダンの分離のための方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
BRPI0620659A2 (pt) 2005-12-09 2017-10-31 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd método para a prevenção do aparecimento de sintomas de uma doença neurodegenerativa em um indivíduo predisposto à doença neurodegenerativa, método de redução de stress oxidante no cérebro de um indivíduo afligido com stress oxidante, método de tratamento de um indivíduo afligido com a degeneração cognitiva suave e composição farmacêutica
CA2643235C (en) 2006-02-21 2014-06-17 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
JP5769923B2 (ja) 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
DE202006020710U1 (de) 2006-05-09 2009-12-31 Teva Pharmaceutical Industries Ltd. Zusammensetzungen mit Rosiglitazonmaleat
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
NZ577623A (en) 2006-12-14 2011-05-27 Teva Pharma Tannate salt of rasagiline
NZ577460A (en) * 2006-12-14 2012-01-12 Teva Pharma Crystalline solid rasagiline base
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
CA2698695A1 (en) * 2007-09-05 2009-03-12 Teva Pharmaceutical Industries Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
CN101909438A (zh) * 2008-01-11 2010-12-08 泰华制药工业有限公司 雷沙吉兰制剂、其制备及用途
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
EP2271612B1 (en) * 2008-03-31 2016-08-10 Actavis Group PTC EHF Rasagiline mesylate particles and process for the preparation thereof
WO2009151625A1 (en) * 2008-06-13 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline for parkinson's disease modification
EP2299993A4 (en) * 2008-06-19 2014-08-20 Teva Pharma PROCESS FOR PURIFYING THE BASE OF RASAGILINE
EP2299992A4 (en) * 2008-06-19 2015-10-21 Teva Pharma PROCESS FOR THE PREPARATION AND DRYING OF A SOLID RASAGILINE BASE
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
KR20110130410A (ko) 2009-03-05 2011-12-05 산도즈 아게 라사길린 메실레이트를 함유하는 제약 조성물
US8946482B2 (en) 2009-07-09 2015-02-03 Ratiopharm Gmbh Salts of rasagiline and pharmaceutical preparations thereof
CN102048717B (zh) † 2009-10-29 2014-02-19 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物
EP2515891A4 (en) 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
AU2011248904B2 (en) 2010-04-30 2014-02-27 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
EP2389927A1 (en) 2010-05-30 2011-11-30 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Pharmaceutical formulations of rasagiline
CA2806737A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersions of rasagiline citrate
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
JP5906302B2 (ja) 2011-03-24 2016-04-20 テイコク ファーマ ユーエスエー インコーポレーテッド 作用剤層および作用剤変換層を含む経皮組成物
CA2851274A1 (en) * 2011-10-10 2013-04-18 Konstantin Ulanenko Rasagiline citramide
EA201490760A1 (ru) 2011-10-10 2014-09-30 Тева Фармасьютикал Индастриз Лтд. R(+)-n-метилпропаргиламиноиндан
BR112014008555A2 (pt) * 2011-10-10 2017-04-18 Teva Pharma r(+)-n-formil-propargil-aminoindano
US9913812B2 (en) 2011-11-09 2018-03-13 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
DE102012000786A1 (de) 2012-01-18 2013-07-18 Stada Arzneimittel Ag Verfahren zur Herstellung einer festen pharmazeutischen Zusammensetzung, enthaltend den Wirkstoff Rasagilin
EA201491734A1 (ru) 2012-03-21 2015-01-30 Синтон Бв Стабилизированные фармацевтические композиции, содержащие соли разагилина
WO2013175493A1 (en) 2012-04-09 2013-11-28 Cadila Healthcare Limited Stable oral pharmaceutical compositions
MX2015002062A (es) 2012-08-17 2015-06-05 Teva Pharma Formulaciones parenterales de rasagilina.
KR101856515B1 (ko) 2012-11-02 2018-05-10 테이코쿠 팔마 유에스에이, 인코포레이티드 프로피닐아미노인단 경피 조성물
EP2796130A3 (en) * 2013-02-06 2015-02-25 Galenicum Health S.L. Immediate release tablets of rasagiline hemitartrate
ES2502140T1 (es) * 2013-02-06 2014-10-02 Galenicum Health S.L. Comprimidos de liberación inmediata de rasagilina hemitartrato
CN115400090A (zh) * 2022-10-09 2022-11-29 北京新领先医药科技发展有限公司 一种雷沙吉兰的口崩片组合物及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
GB8909793D0 (en) * 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
CA2039742A1 (en) * 1990-04-23 1991-10-24 Andrew B. Dennis Tablet composition and method for problem pharmaceutical materials
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL112779A (en) * 1994-03-01 1999-11-30 Gergely Gerhard Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
JP3273141B2 (ja) * 1995-03-02 2002-04-08 アール． ピー． シェーラー リミテッド モノアミンオキシダーゼｂインヒビターからなる医薬組成物

Also Published As

Publication number Publication date
US6126968A (en) 2000-10-03
AU728524B2 (en) 2001-01-11
HU225859B1 (en) 2007-11-28
HUP9802999A2 (hu) 1999-04-28
PT858328E (pt) 2007-08-20
DE69637096D1 (de) 2007-07-05
IL115357A (en) 2000-01-31
DE69637096T2 (de) 2008-01-31
WO1997012583A3 (en) 1997-06-05
ATE362755T1 (de) 2007-06-15
JP4108750B2 (ja) 2008-06-25
AU6942796A (en) 1997-04-28
CA2232310C (en) 2008-01-08
CA2232310A1 (en) 1997-04-10
IL115357A0 (en) 1995-12-31
HUP9802999A3 (en) 1999-05-28
EP0858328A2 (en) 1998-08-19
JPH11512736A (ja) 1999-11-02
WO1997012583A2 (en) 1997-04-10
EP0858328B1 (en) 2007-05-23
ES2287940T3 (es) 2007-12-16
EP0858328A4 (en) 2001-07-11

Similar Documents

Publication Publication Date Title
DK0858328T3 (da) Stabile præparater indeholdende N-propargyl-1-aminoindan
UA26455C2 (uk) Лікарський препарат у формі таблеток із сповільhеhим вивільhеhhям активhого іhгредієhта
FR2688422B1 (da)
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
ZA948670B (en) New benzoyl guanidine derivatives,the preparation thereof and their use in pharmaceutical compositions
EP1468679A3 (en) Controlled release formulation containing tramadol
PT881901E (pt) Novas associacoes de principios activos contendo clopidogrel e um agente anti-trombotico
NO972623L (no) Farmasöytisk blanding omfattende lamotrigin
IT1272149B (it) Composizione farmeceutiche ad attivita' analgesica
CA2203310A1 (fr) Comprime matriciel permettant la liberation prolongee du sel de sodium de tianeptine apres administration par voie orale
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
ES2124256T3 (es) Arilmorfolina, preparacion y uso.
CA2152998A1 (en) Anti-hyperglycemia pharmaceutical composition
AU2774292A (en) Toiletries composition
HUP9902415A2 (hu) Azonnal felszabaduló szilárd beadási formák és eljárás azok előállítására
AU3749195A (en) Bis-2-aminopyridines, preparation method therefor and use tereof for controlling parasitic infections
NO950177L (no) Farmakologisk aktive erivater
ATE234096T1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
IL122853A0 (en) Use of allylamines
KR950700743A (ko) 프로스타사이클린류를 활성성분으로서 함유하는 외용 피부치료제 조성물(dermatologic preparation composition containing prostacyclin as active ingredient)
TW333453B (en) Pharmaceutical composition comprising toremifene for use in the treatment of autoimmune diseases
MX9605633A (es) Composicion farmaceutica, metodo y dispositivo para prevenir o tratar resequedad de los ojos o enfermedad ocasionada por la misma.
JO1750B1 (en) Substituted benzimidazole compounds, practical to prepare and use